Current and future nanoparticle vaccines for COVID-19

Mai N. Vu; Hannah G. Kelly; Stephen J. Kent; Adam K. Wheatley

doi:10.1016/j.ebiom.2021.103699

Current and future nanoparticle vaccines for COVID-19

Mai N. Vu, Hannah G. Kelly, Stephen J. Kent, Adam K. Wheatley

Research output: Contribution to journal › Review Article › Research › peer-review

49 Citations (Scopus)

Abstract

COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.

Original language	English
Article number	103699
Number of pages	10
Journal	EBioMedicine
Volume	74
DOIs	https://doi.org/10.1016/j.ebiom.2021.103699
Publication status	Published - Dec 2021

Keywords

COVID-19 vaccine
nanoparticle vaccine
neutralizing antibody
protein nanoparticle
SARS-CoV-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ebiom.2021.103699Licence: CC BY-NC-ND

Cite this

@article{ff2abc99b0594d02b1d932e7baeb3a54,

title = "Current and future nanoparticle vaccines for COVID-19",

abstract = "COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.",

keywords = "COVID-19 vaccine, nanoparticle vaccine, neutralizing antibody, protein nanoparticle, SARS-CoV-2",

author = "Vu, {Mai N.} and Kelly, {Hannah G.} and Kent, {Stephen J.} and Wheatley, {Adam K.}",

note = "Funding Information: This work was supported by the Australian Research Council (ARC) Centre of Excellence in Convergent Bio-Nano Science and Technology (Project No. CE140100036). M.N.V. acknowledges the financial support from Monash Graduate Scholarship (MGS) and Monash International Postgraduate Research Scholarship (MIPRS). SJK and AKW are supported by NHMRC fellowships. Funding sources were not involved in the decision to submit this review for publication or in the writing of this review. Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = dec,

doi = "10.1016/j.ebiom.2021.103699",

language = "English",

volume = "74",

journal = "EBioMedicine",

issn = "2352-3964",

publisher = "The Lancet Publishing Group",

}

TY - JOUR

T1 - Current and future nanoparticle vaccines for COVID-19

AU - Vu, Mai N.

AU - Kelly, Hannah G.

AU - Kent, Stephen J.

AU - Wheatley, Adam K.

N1 - Funding Information: This work was supported by the Australian Research Council (ARC) Centre of Excellence in Convergent Bio-Nano Science and Technology (Project No. CE140100036). M.N.V. acknowledges the financial support from Monash Graduate Scholarship (MGS) and Monash International Postgraduate Research Scholarship (MIPRS). SJK and AKW are supported by NHMRC fellowships. Funding sources were not involved in the decision to submit this review for publication or in the writing of this review. Publisher Copyright: © 2021 The Authors

PY - 2021/12

Y1 - 2021/12

N2 - COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.

AB - COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.

KW - COVID-19 vaccine

KW - nanoparticle vaccine

KW - neutralizing antibody

KW - protein nanoparticle

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85119372798&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2021.103699

DO - 10.1016/j.ebiom.2021.103699

M3 - Review Article

C2 - 34801965

AN - SCOPUS:85119372798

SN - 2352-3964

VL - 74

JO - EBioMedicine

JF - EBioMedicine

M1 - 103699

ER -

Current and future nanoparticle vaccines for COVID-19

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology

Cite this

Current and future nanoparticle vaccines for COVID-19

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Projects

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology

Cite this